October 12, 2017
1 min read

Platelet count recovers after SVR in HCV, disrupted by HBV coinfection

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Patients treated for hepatitis C who achieved sustained virologic response recovered platelet counts, according to recently published data. Hepatitis B coinfection, however, disrupted platelet count recovery, especially in patients with advanced liver disease from chronic HCV.

“Taken collectively, it is postulated that the factors associated with [platelet] recovery may be linked to fibrotic regression,” the researchers wrote. “Interestingly, we noticed that HBV co-infection was associated with slow [platelet] recovery. The result hints that HBV co-infection may interfere with fibrotic regression in patients with curative HCV infection.”

The study comprised 466 patients whom researchers followed for an average 85.5 months (range, 12-163 months) after they achieved SVR for HCV. Fifty patients were coinfected with HBV. The proportion of patients with fibrosis stage 0 to 1 was 38.5%, 32% for stage 2, 17.6% for stage 3, and 12% for stage 4.

At both baseline and follow-up, platelet counts decreased as fibrosis stage increased (P < .001). However, platelet counts increased significantly after SVR among all patients regardless of fibrosis stage (P < .001), except for patients with HBV coinfection and fibrosis stage 3 or 4.

Factors associated with slower platelet count recovery included high pretreatment platelet counts (OR = 0.992; 95% CI, 0.989-0.996) and HBV coinfection (OR = 0.416; 95% CI, 0.22-0.785).

For patients with fibrosis stage 0 to 2, high platelet count at baseline affected the rate of platelet recovery (OR = 0.992; 95% CI, 0.987-0.996). Among those with fibrosis stage 3 or 4, HBV was the only significant factor that affected the rate of platelet recovery (OR = 0.207; 95% CI, 0.054-0.789).

“We demonstrated that platelet counts decreased progressively in proportion to the advancement of liver fibrosis in [chronic HCV] patients before antiviral therapy,” the researchers concluded. “Importantly, we noticed that HBV co-infection may refrain patients from raid platelet recovery. Of particular note was that the condition existed only in patients with advanced liver disease.” – by Talitha Bennett

Disclosure: The authors report no relevant financial disclosures.